Selling, General, and Administrative Costs: AstraZeneca PLC vs Axsome Therapeutics, Inc.

A Tale of Two Companies: AstraZeneca vs. Axsome Therapeutics

In the world of pharmaceuticals, the financial strategies of companies can be as varied as their drug portfolios. AstraZeneca PLC, a global leader in biopharmaceuticals, and Axsome Therapeutics, Inc., a burgeoning player in the field, offer a fascinating contrast in their Selling, General, and Administrative (SG&A) expenses over the past decade.

AstraZeneca's Steady Climb

From 2014 to 2023, AstraZeneca's SG&A expenses have shown a consistent upward trend, peaking in 2022 with a 42% increase from 2014. This reflects the company's expansive global operations and robust marketing strategies.

Axsome's Rapid Growth

Conversely, Axsome Therapeutics has experienced a staggering growth in SG&A expenses, skyrocketing by over 23,000% from 2014 to 2023. This surge underscores Axsome's aggressive expansion and investment in its pipeline.

This comparison highlights the diverse financial strategies within the pharmaceutical industry, driven by each company's unique growth trajectory and market positioning.